Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.44 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718287 | 1.00 | NR1I2 (0.44) | NR1I2CYP2E1LMNA | |
| SCHEMBL14645145 | 1.00 | NR1I2 (0.44) | NR1I2CYP2E1LMNA | |
| SCHEMBL14645162 | 0.90 | NR1I2 (0.36) | NR1I2CYP2E1 | |
| SCHEMBL14645161 | 0.90 | NR1I2 (0.36) | NR1I2CYP2E1 | |
| SCHEMBL15015373 | 0.87 | NR1I2 (0.45) | NR1I2CYP2E1LMNA | |
| SCHEMBL15130774 | 0.86 | NR1I2 (0.42) | NR1I2CYP2E1 | |
| SCHEMBL15132469 | 0.86 | NR1I2 (0.42) | NR1I2CYP2E1 | |
| SCHEMBL15130851 | 0.86 | NR1I2 (0.42) | NR1I2CYP2E1 | |
| SCHEMBL14726720 | 0.85 | LMNA (0.33) | LMNA | |
| SCHEMBL14726729 | 0.85 | LMNA (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734515-B1 | THIOPHEN-2-CARBOXYLIC ACID DERIVATIVES USEFUL AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-8741946-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741946-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741946-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130052161-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130052161-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052161-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 60/4885CYP2E1 4/4885LMNA 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.